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Background: Adhesion molecules, such as platelet-endothelial adhesion molecule-1 (PECAM-1), platelet selectin
(P-selectin), endothelial selectin (E-selectin), intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion
molecule-1 (VCAM-1), are localized on the membranes of activated platelets and leukocytes and on the vascular
endothelium. Recently, we measured serum levels of soluble (s) forms of adhesion molecules in adults,18 to 26
years old, with autism spectrum disorder (ASD) and observed low levels of sPECAM-1 and sP-selectin. A subsequent
study showed a similar result in children two to four years old with ASD. However, information about school age
(five to seventeen years old) ASD subjects is required to determine whether adhesion molecules are also reduced
in individuals with ASD in this age range.
Findings: Twenty-two subjects with high-functioning ASD and 29 healthy age-matched controls were recruited.
ELISA was used for sPECAM-1, and a suspension array system was used for sP-selectin, sE-selectin, sICAM-1 and
sVCAM-1 measurements. We found that serum levels of sPECAM-1 (U = 91.0, P<0.0001 by Mann–Whitney U test)
and sVCAM-1 (U = 168.0, P = 0.0042) were significantly lower in ASD subjects than in controls. Subsequently, we
examined the correlations between serum levels of either sPECAM-1 or sVCAM-1 and clinical variables including
Autism Diagnostic Interview - Revised subscores and our previous cytokine profile data from the same ASD
subjects. However, we did not find any significant correlations between them.
Conclusions: The present results, taken together with previous results, suggest that sPECAM-1 may play a role in
the generation and development of ASD, beginning in childhood and lasting until adulthood.
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Background
Autism spectrum disorder (ASD) is a developmental dis-
order that is characterized by severe impairment in so-
cial interaction and communication and by the presence
of stereotyped behavior. The mechanisms underlying
the pathophysiology of this disorder remain to be deter-
mined [1,2]. However, accumulating evidence suggests
that the immune system plays a role in the pathophysi-
ology of ASD [3-5].
Adhesion molecules, such as platelet-endothelial adhe-
sion molecule-1 (PECAM-1), platelet selectin (P-selectin),
endothelial selectin (E-selectin), intracellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion mole-
cule-1 (VCAM-1) are localized on the membranes of
activated platelets and leukocytes and on the vascular
endothelium [6,7]. They mediate the binding of leukocytes
to the blood vessel wall, which is the main step in the
process of inflammation [6,7]. Soluble PECAM-1 exists in
a 90 kDa cleaved form and a 120 kDa form produced by
mRNA alternative splicing, both of which are present at
approximately equal levels in plasma [8].We previously
measured serum levels of soluble (s) forms of the adhesion
molecules in adults (18 to 26 years of age) with high-
functioning ASD [9,10]. We found that the levels of
sPECAM-1 and sP-selection were significantly decreased
in ASD adults compared with controls [9,10], while
sVCAM-1 showed a weak trend towards a lower level
[10]. Children with ASD (two to four years of age) have
significantly lower levels of sPECAM-1 and sP-selectin
compared with controls [11]. Taken together, these results
suggest that adhesion molecules may be involved in the
pathophysiology of ASD. However, serum levels of adhe-
sion molecules in school-age (five to seventeen years of
age) ASD subjects have not been examined. Moreover, it
is still unclear how they relate to immune abnormalities
or inflammatory phenotypes of ASD. In the present study,
we measured serum levels of sPECAM, sP-selectin, sE-
selectin, sICAM-1 and sVCAM-1 in males five to seven-
teen years of age, with high-functioning ASD. A recent
systemic serum proteome profiling study reported that
males and females with Asperger’s disorder have distinct
biomarker fingerprints [12]. It has been argued that gen-
etic variation for ASD and intellectual disability cluster in
genes involved in distinct pathways and protein complexes
[13]. Therefore, to prevent any potential confounding
effects of sex and intelligence, we recruited only high-
functioning males. Subsequently, we tested the relation-
ships between serum levels of adhesion molecules and
clinical variables in high-functioning ASD subjects. Ad-
ditionally, we examined the correlation between adhesion
molecules and the significantly-altered cytokine profile of
this population according to our previous cytokine profile
data [14].Methods
Ethics approval
This study received approval from the ethics committee
of the Hamamatsu University School of Medicine. All
participants gave written informed consent before volun-
tary enrollment.
Subjects
Twenty-two male subjects with high-functioning ASD
(five to seventeen years of age) and 29 age-matched
(eight to sixteen years of age) and healthy male control
individuals were included in this study. All the partici-
pants were Japanese, born and living in the Aichi, Gifu
or Shizuoka Prefectures of central Japan.
Based on interviews and available records, including
those from hospitals, the diagnosis of autism was made
based on the Diagnostic and Statistical Manual, fourth
edition, text revision (DSM-IV-TR) criteria. The Autism
Diagnostic Interview-Revised (ADI-R) was also conduc-
ted by two of the authors (KJT and KM), who are ex-
perienced and reliable at diagnosing autism with the
Japanese version of the ADI-R [15]. ADI-R is a semi-
structured interview conducted with a parent, usually
the mother, and is used to confirm the diagnosis and
evaluate the core symptoms of autism [15]. We also used
the Wechsler Intelligence Scale for Children, third edi-
tion (WISC-III), to exclude subjects with a full-scale IQ
of less than 70. Comorbid psychiatric illnesses were ex-
cluded using the Structured Clinical Interview for DSM-
IV (SCID). Participants were excluded from the study if
they had any symptoms of inflammation, a diagnosis of
autoimmune disease, fragile X syndrome, epileptic sei-
zures, obsessive-compulsive disorder, affective disorder,
or any additional psychiatric or neurological diagnosis.
All the autistic subjects were drug-naive and were not
taking any dietary supplements.
Healthy control subjects were recruited locally by ad-
vertisement. All control subjects underwent a compre-
hensive assessment of their medical history to eliminate
individuals with neurological or other medical disorders.
SCID was conducted to scrutinize any personal or family
history of past or present mental illness. None of the
control subjects initially recruited fulfilled any of these
exclusion criteria.
Sampling and assay
Serum samples were collected as described previously
[9,10]. Serum levels of sPECAM-1/CD31 were determi-
ned using the appropriate commercially available sand-
wich ELISA kits (Instant ELISA, eBioscience, San Diego,
CA, USA) according to the manufacturer’s instructions.
Serum levels of the other adhesion molecules were as-
sayed with a suspension array system (Bio-Plex; BioRad,
Hercules, CA USA), using a Fluorokine MAP Multiplex
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Minneapolis, MN, USA), including human sE-selectin/
CD62E, sP-selectin/CD62P, sICAM-1/CD54, and sVCAM-
1/CD106. Multiplex kits for measuring cytokines including
IL-1β, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and
growth-related oncogene (GRO)-α were purchased from
Bio-Rad (Bio-Plex Pro Human Cytokine Group I (27-plex)
and Group II (21-plex) panels). This system allows simul-
taneous identification of adhesion molecules with anti-
bodies chemically attached to fluorescently labeled micro-
beads. The beads were resuspended in assay buffer and the
reaction mixture was quantified using a Bio-Plex protein
array reader. The sera of all subjects with high-functioning
ASD were measured together in one assay with a set of
control sera. Each serum sample was analyzed in duplicate,
and the mean value of the two measures was used for the
analyses. Concentrations (pg/ml) of different analytes in
the serum samples were determined by using standard
curves generated in the multiplex assays. Each standard
curve was generated using eight points of concentrations,
and a nonlinear least squares minimization algorithm was
used for the curve fitting by the 5PL equation which deter-
mines the high and low limits of detection. To exclude in-
flammatory disease, serum C-reactive protein (CRP) levels
were determined using a routine clinical biochemistry
automatic analyzer.
Performance characteristics of the immunoassays
Sensitivity
The limit of detection of the assays, defined as the ana-
lyte concentration resulting in an absorbance signifi-
cantly higher than that of the dilution medium (mean plus
2 standard deviations), was determined to be 0.06 ng/ml
(human sPECAM-1), 2.4 pg/ml (human sICAM-1), 4.2
pg/ml (human sP-Selectin), 0.55 pg/ml (human sE-
Selectin), and 1.72 pg/ml (human sVCAM-1).
Reproducibility
Reproducibility within the assay was evaluated in three
independent experiments. Each assay was performed
with six replicates of eight serum samples containing
different concentrations of the analyte. The calculated
overall intra-assay coefficient of variation was 7.0% (hu-
man sPECAM-1), 6.2% (human sICAM-1), 6.1% (human
sP-Selectin), 5.3% (human sE-Selectin), and 5.2% (human
sVCAM-1). The calculated overall inter-assay coefficient
of variation was 4.2% (human sPECAM-1), 17.7%
(human sICAM-1), 12.7% (human sP-Selectin), 13.4%
(human sE-Selectin), and 14.7% (human sVCAM-1).
Recovery
The spike recovery was evaluated by spiking four levels
of human sPECAM-1 into human serum. Recoveries
were determined in three independent experiments withsix replicates each. The unspiked serum was used as a
blank in these experiments. The average recovery ranged
from 94% to 121% with an overall mean recovery of
107%. In the suspension array system, cell culture media
samples were spiked with a recombinant analyte and eval-
uated for recovery. The average recovery was 99% (human
sICAM-1: range 83 to 112%), 104% (human sP-Selectin:
range 85 to 118%), 104% (human sE-Selectin: range 95 to
113%), and 98% (human sVCAM-1: range 85 to 112%).
Statistical analysis
Clinical characteristics (age, weight, height, body mass
index (BMI) and CRP) were analyzed using an unpaired
t test, after confirmation that there were no significant
differences in variance as assessed by the F test. Com-
parisons of concentrations of sPECAM-1, sE-selectin,
sP-selectin, sICAM-1, and sVCAM-1 between ASD sub-
jects and controls were made using the Mann–Whitney
U test because of significant differences in variance as
assessed by the F test. Evaluation of the relationships be-
tween levels of both sPECAM-1 and sVCAM-1 and clin-
ical variables or symptom profiles was performed using
Spearman’s rank correlation coefficient. Values of P<0.05
were considered significant. All statistical analyses were
performed using SPSS software (version 18.0 J; IBM,
Tokyo, Japan).
Results and discussion
The characteristics of all the participants are summa-
rized in Table 1. There were no significant differences in
the distributions of age, weight, height and BMI between
the subjects with high-functioning ASD and the con-
trols. There were also no significant differences in CRP
between the high-functioning ASD and the control
groups.The CRP measurement of one subject with ASD
was 2.30 mg/dl (this individual did not have subjective
symptoms or a history of inflammatory disease). There
were no significant differences in a full-scale IQ of
WISC-III.
The serum levels of sPECAM-1 in subjects with high-
functioning ASD were significantly lower than those of
controls (U = 91.0, P<0.0001) (Table 1). Subjects with
high-functioning ASD also had significantly decreased
levels of sVCAM-1 compared with those in controls
(U = 168.0, P = 0.0042) (Table 1). There were no signifi-
cant differences in sE-selectin, sP-selectin, and sICAM-1
levels between high-functioning ASD subjects and con-
trols (U = 298.0, P = 0.6966 for sE-selectin; U = 268.0,
P = 0.3369 for sP-selectin; and U = 302.0, P = 0.9144 for
sICAM) (Table 1).
We then examined the correlations between serum
levels of either sPECAM-1 or sVCAM-1 and clinical
variables among ASD subjects. Neither sPECAM-1 nor
sVCAM-1 levels had significant correlations with clinical
Table 1 Clinical characteristics of control individuals and subjects with high-functioning ASD
Group Control (number = 29) ASD (number = 22) P-value
Age, years 11.6 ± 1.9 (8 to 16) 11.5 ± 3.2 (5 to 17) NS
Weight, kg 40 ± 9.9 (24 to 57.6) 41.4 ± 16.5 (17.5 to 96.6) NS
Height, cm 149.3 ± 11.9 (121.4 to 167) 147 ± 18.3 (110 to 178) NS
BMI, kg/m2 17.7 ± 2.3 (14.4 to 25.3) 18.5 ± 3.5 (13.9 to 30.5) NS
CRP, mg/dl 0.02 ± 0.02 (0.01 to 0.08) 0.13 ± 0.44 (0.01 to 2.30) NS
ADI-R
Domain A score N/A 20.7 ± 5.0 (10 to 27)
Domain BV score N/A 14.2 ± 4.2 (8 to 21)
Domain C score N/A 5.3 ± 2.0 (3 to 9)
Domain D score N/A 3.2 ± 1.0 (2 to 5)
Sum N/A 43.5 ± 9.6 (28– to 0)
WISC-III
Full-scale IQ 103.5 ± 13.1 (82 to 129) 97.2 ± 17.7 (72 to 134) NS
Adhesion molecules
sPECAM-1 (ng/ml) 77.8 ± 13.2 (41.9 to 99.3) 58.4 ± 12.5 (36.4 to 82.4) <0.0001
sE-Selectin (micro g/ml) 44.8 ± 13.2 (24.1 to 89.7) 42.9 ± 19.1 (13.1 to 93.2) NS
sP-Selectin (micro g/ml) 69.5 ± 21.2 (38.9 to 125.5) 78.1 ± 28.9 (39 to 137.5) NS
sICAM-1 (micro g/ml) 325.8 ± 41.5 (243.8 to 422.1) 323.3 ± 56.4 (223.5 to 428.2) NS
sVCAM-1 (micro g/ml) 916.5 ± 106.6 (749.4 to 1160.8) 810.5 ± 146.8 (561.8 to 1162.5) 0.0042
Values are expressed as mean ± s.d. (range). ADI-R Autism Diagnostic Interview-Revised, ASD autism spectrum disorder, BMI body mass index, CRP C-reactive protein,
ICAM-1 intracellular adhesion molecule-1, IQ intelligence quotient, N/A not applicable, NS not significant, PECAM-1 platelet-endothelial adhesion molecule-1, s soluble,
VCAM-1 vascular cell adhesion molecule-1, WISC-III Wechsler Intelligence Scale for Children, Third Edition.
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R subscale scores and full-scale IQ (data not shown).
We determined that plasma concentrations of IL-1β, IL-
1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-α
were significantly higher in subjects with ASD compared
with the corresponding values of the matched controls,
after correcting for multiple comparisons [14]. Subse-
quently, we examined the correlations between serum
levels of either sPECAM-1 or sVCAM-1 and our previ-
ous cytokine profile data from the same ASD subjects.
However, we did not find any significant correlations bet-
ween them (Table 2). Our finding of low serum levels of
sPECAM-1 and sVCAM-1 in the present study provides
further support of previous reports that adhesion mole-
cules may have a role in the pathophysiology of ASD, pos-
sibly by causing abnormalities in the immune system
[14,16]. Similar to our subjects with ASD (five to seven-
teen years of age), children (two to four years of age) [11]
and adults (18 to 26 years of age) [10] with ASD also have
low levels sPECAM-1. However, sVCAM-1 levels are not
altered in ASD children [11], but there is a weak trend to-
wards lower levels in ASD adults [10]. Our results of re-
duced levels of sVCAM-1 in the current study appear to
be compatible with those obtained in ASD adults, who
show a tendency towards a decrease in sVCAM-1 levels.Therefore, we propose that sVCAM-1 may play a limited
role in the pathophysiology of ASD. These findings sug-
gest that sPECAM-1 may play an important role in the
generation and development of the pathophysiology of
ASD, beginning in childhood and lasting until adulthood.
PECAM-1 has been implicated as an important mediator
for the transendothelial migration of leukocytes in vivo
and in vitro [17]. However, the requirement for PECAM
in the transmigration of leukocytes is not absolute [18].
Rather, the absence of PECAM may facilitate the migra-
tion of leukocytes across the blood–brain barrier, presum-
ably due to compensation by other adhesion molecules
[19]. For instance, during progression of experimental
autoimmune encephalomyelitis (a model for multiple
sclerosis), mononuclear cell extravasation and infiltration
of the brain in PECAM-1-deficient mice are considerably
enhanced [18]. Additionally, cultured PECAM-1-deficient
endothelial cells in mice exhibit prolonged changes in re-
sponse to histamine treatment [18]. Recently, our mea-
surements with positron emission tomography showed
that adults with high-functioning ASD have significantly
increased activated microglia in a wide range of brain
areas [20]. Decreased sPECAM-1 levels might facilitate
the infiltration and accumulation of leukocytes in the
brain, leading to an increase in activated microglia.
Table 2 Correlation between the adhesion molecules
and cytokines of control individuals and subjects with
high-functioning ASD
Control ASD
Analytes CC number P-value CC number P-value
sVCAM-1
IL-1β 0.009 29 NS 0.383 22 NS
IL-1RA −0.265 29 NS 0.055 22 NS
IL-5 −0.158 29 NS 0.011 22 NS
IL-8 −0.159 29 NS 0.281 22 NS
IL-12 (p70) −0.050 28 NS 0.333 22 NS
IL-13 −0.240 29 NS 0.144 22 NS
IL-17 0.195 10 NS 0.215 16 NS
GRO-α −0.256 25 NS 0.269 21 NS
sPECAM-1
IL-1β 0.102 29 NS −0.100 22 NS
IL-1RA −0.056 29 NS −0.067 22 NS
IL-5 −0.134 29 NS 0.126 22 NS
IL-8 −0.063 29 NS −0.205 22 NS
IL-12 (p70) 0.132 28 NS 0.008 22 NS
IL-13 0.227 29 NS −0.106 22 NS
IL-17 −0.109 10 NS −0.056 16 NS
GRO-α −0.136 25 NS −0.064 21 NS
ASD autism spectrum disorder, CC correlation coefficient, GFO-α growth-related
oncogene α, NS not significant, PECAM-1 platelet-endothelial adhesion
molecule-1, s soluble, VCAM-1 vascular cell adhesion molecule-1.
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ther sPECAM-1 or sVCAM-1 and clinical variables in-
cluding ADI-R subscores and serum levels of ILs, no
overt interrelationship was observed. In this test, we
were focusing on IL-8 and GRO-α, in particular, because
both are chemokines produced by macrophages and
other cell types, such as epithelial and endothelial cells.
These chemokines have chemotactic activity on neutro-
phils and play an important role in the innate immune
response. Previous studies have examined IL-8 levels in
plasma or serum and found either increased [21] or no
change [12,22] in peripheral IL-8 levels. The reason why
these chemokines are increased in subjects with ASD is
currently unknown [14]. However, our result suggests
that reduced levels of sPECAM-1 and sVCAM-1 are not
involved in the clinical aspects or IL alterations of
school-aged boys with ASD. These alterations of adhesion
molecules may be caused by events besides a known in-
flammation signaling in subjects with ASD. In contrast,
Onore et al. observed significant associations between
PECAM-1 levels and higher repetitive behavior scores in
ASD children [11]. It is, therefore, of interest to examine
the correlation between serum levels of PECAM-1 and in-
terleukins in very young children with and without autismto clarify how these adhesion molecules in serum may re-
flect their central function associated with clinical aspects
of ASD.
There are limitations to the present study. The small
sample size renders the data preliminary, and a larger
study with more subjects with ASD is necessary. How-
ever, recruitment for the current study was limited to a
group of high-functioning male subjects with ASD (these
subjects were not given psychotropic drugs). Therefore,
our data are free from confounding factors due to sex,
intelligence and psychotropic drugs and, thus, reflect a
certain common immunological pathology among people
with ASD. Moreover, the samples were measured in dupli-
cate. Although triplicate measures were recommended to
exclude any spurious measurements, in the present study
we could not ensure that there were enough serum sam-
ples for triplicate measurements.
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